Zimmer BiometZBH.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Zimmer Biomet (ZBH.N) trades at a P/E of 22.50x, P/B of 1.44x, P/S of 2.13x, and a dividend yield of 0.76%.
Longitudinal percentile comparison: P/E sits at the 27th percentile over the trailing 10Y window (vs. 40th percentile over 3Y); P/B sits at the 7th percentile over the trailing 10Y window (vs. 24th percentile over 3Y); P/S sits at the 5th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 47th percentile within its industry and the 58th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.45%, ranking at the 52nd percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 19.3 points — relying on either metric alone could be misleading. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Breaking down the total shareholder yield: 0.76% comes from cash dividends, with an implied ~2.69% from buybacks — a fairly balanced mix of both channels. Zimmer Biomet operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: ZBH · ZBH
Want the full picture on whether Zimmer Biomet (ZBH.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 22.50 | ||||||
| P/B (MRQ) | 1.44 | ||||||
| P/S (TTM) | 2.13 | ||||||
| Dividend Yield | 0.76% | ||||||
| Buyback + Div Yield | 3.45% |